Lecanemab

© GettyImages/Frank Brennan

ADDF: Anti-amyloids are a promising starting point

By Jane Byrne

The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer’s will require drugs that do more than clear amyloid plaques, says the Alzheimer’s...